The EBiSC team is working hard to implement improvements in how EBiSC operates.
Due to some short-term disruption, please get in touch via
Contact@EBiSC.org if
the cells you would like to access are currently listed as unavailable or you
are ordering from outside of Europe.
EDi001-A-1
AST22-C, AST23-C
Gene-edited iPSC line
We are currently making some changes to how EBiSC operates and because
of this there is a short period of time where orders cannot be placed.
If you are interested in accessing these cells, please contact EBiSC directly. For more information about the current transition process see here.
If you are interested in accessing these cells, please contact EBiSC directly. For more information about the current transition process see here.
You will need to complete a Cell Line Information Pack (CLIP) before purchasing your cell line.
Please contact us to receive the relevant document.
The EBiSC Access and Use Agreement must be completed along with an individual
Cell Line Information Pack for each line. Complete the EAUA and send to Contact@EBiSC.org
for countersignature. The EAUA must be fully signed before proceeding with your order.
To receive the Certificate of Analysis, please contact us.
A batch specific Certificate of Analysis will be available to
download once you receive your EBiSC iPSC line.
General#
Cell Line |
|
hPSCreg name | EDi001-A-1 |
Alternative name(s) |
AST22-C, AST23-C
|
Cell line type | Human induced pluripotent stem cell (hiPSC) |
Similar lines |
EDi001-A-3 (AST23_SNCAKO Clone 1, AST22-1KO-1, AST23-1KO-1, AST22_SNCAKO Clone 1) Donor's gene variants: SNCA, SNCA, SNCA, SNCA Donor diseases: Parkinson disease EDi001-A-2 (AST23-1KO-3, AST22-1KO-3, AST-23_SCAKO Clone 3, AST-22_SNCAKO Clone 3) Donor's gene variants: SNCA, SNCA, SNCA, SNCA Donor diseases: Parkinson disease EDi001-A (AST22, AST23, SAMEA3319992) Donor's gene variants: SNCA, SNCA, SNCA Donor diseases: Parkinson disease EDi008-B (G51D-4, EDINi008-B, EDIi008-B, SAMEA3174606) Donor's gene variants: SNCA, SNCA, SNCA, SNCA Donor diseases: Parkinson disease STBCi004-B-1 (SFC832-03-06 LRRK2WT/WT C47) Donor's gene variants: LRRK2 Donor diseases: Parkinson disease |
Provider |
|
Depositor | University of Edinburgh (ED) |
Owner | College of Medicine and Veterinary Medicine |
Distributors |
EBiSC
Roslin Cells (RC)
|
Derivation country | United States |
External Databases |
|
hPSCreg | EDi001-A-1 |
BioSamples | SAMEA3323836 |
Cellosaurus | CVCL_LE51 |
Wikidata | Q54831972 |
General Information |
|
Publications | View all related publications on hPSCreg (1) |
This EBiSC line can be used for: |
Yes
Research use: allowed
Clinical use: no
Commercial use: no
|
Subclone of | (not in EBiSC, see EDi001-A in hPSCreg) |
Donor Information#
General Donor Information |
|
Sex | female |
Phenotype and Disease related information (Donor) |
|
Diseases | A disease was diagnosed.
|
Disease associated phenotypes |
|
Family history | Strong family history of Parkinson’s disease due to autosomal dominant inheritance of SNCA triplication |
Is the medical history available upon request? | Y Mov Disord. 2011 Sep;26(11):2134-6. doi: 10.1002/mds.23776 |
Karyotyping (Donor) |
|
Has the donor karyotype been analysed? |
No
|
Donor Relations |
|
Other cell lines of this donor |
|
All cell lines of this donor's relatives |
Has daughter:
|
External Databases (Donor) |
|
BioSamples | SAMEA3319991 |
hIPSC Derivation#
General |
|
More source cell information can be found in the parental cell line
EDi001-A in hPSCreg.
|
|
Reprogramming method |
|
Vector type | Integrating |
Vector | Virus (Retrovirus) |
Genes | |
Is the used vector excisable? |
No |
Absence of reprogramming vector(s)? |
Unknown |
Reprogramming vectors silenced? |
Yes |
Methods used |
Immunostaining, RT-PCR
|
Vector free reprogramming |
|
Other |
|
Derived under xeno-free conditions |
No |
Derived under GMP? |
No |
Available as clinical grade? |
No |
Culture Conditions#
The following are the depositor culture conditions, they do not refer to any specific batch.
Surface coating | Laminin | ||||||
Feeder cells |
No |
||||||
Passage method |
Enzymatically
Accutase
|
||||||
O2 Concentration | 95 % | ||||||
CO2 Concentration | 5 % | ||||||
Medium |
Essential 8™
Supplements
|
Characterisation#
Analysis of Undifferentiated Cells
Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
TRA 1-60 |
Yes |
|
||||
SSEA-4 |
Yes |
|
||||
POU5F1 (OCT-4) |
Yes |
|
||||
SSEA-1 |
No |
|
Differentiation Potency
Microbiology / Virus Screening |
|
HIV 1 | Negative |
HIV 2 | Negative |
Hepatitis B | Negative |
Hepatitis C | Negative |
Mycoplasma | Negative |
Genotyping#
Karyotyping (Cell Line) |
|
Has the cell line karyotype been analysed? |
No
|
Other Genotyping (Cell Line) |
Genetic Modification#
Disease/phenotype related modifications |
|